Your browser is no longer supported. Please, upgrade your browser.
Settings
DTIL [NASD]
Precision BioSciences, Inc.
Index- P/E- EPS (ttm)-2.95 Insider Own11.40% Shs Outstand52.35M Perf Week-3.85%
Market Cap578.34M Forward P/E- EPS next Y-2.00 Insider Trans-1.96% Shs Float44.80M Perf Month-16.61%
Income-106.50M PEG- EPS next Q-0.11 Inst Own61.40% Short Float7.50% Perf Quarter-0.95%
Sales22.00M P/S26.29 EPS this Y-135.60% Inst Trans25.11% Short Ratio2.66 Perf Half Y110.62%
Book/sh1.22 P/B9.43 EPS next Y-13.00% ROA-53.10% Target Price18.13 Perf Year38.89%
Cash/sh2.07 P/C5.56 EPS next 5Y- ROE-105.70% 52W Range4.45 - 16.60 Perf YTD37.89%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.72% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low158.14% ATR1.17
Employees223 Current Ratio2.90 Sales Q/Q51.00% Oper. Margin- RSI (14)46.90 Volatility10.64% 9.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.30% Profit Margin- Rel Volume0.73 Prev Close11.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.26M Price11.50
Recom1.80 SMA20-8.79% SMA50-0.76% SMA20036.20% Volume920,289 Change4.36%
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
Apr-22-19Initiated Jefferies Buy
Apr-22-19Initiated Goldman Buy
Apr-22-19Initiated Barclays Overweight
Mar-02-21 12:30PM  
07:00AM  
Feb-19-21 08:32AM  
07:00AM  
Feb-11-21 01:36AM  
Feb-04-21 07:00AM  
Jan-25-21 07:00AM  
Jan-20-21 09:47AM  
Jan-19-21 07:00AM  
Jan-07-21 07:00AM  
Jan-04-21 07:00AM  
Dec-14-20 09:10PM  
12:00AM  
Dec-11-20 11:00AM  
Dec-04-20 06:30AM  
Nov-24-20 04:05PM  
Nov-20-20 07:00AM  
Nov-13-20 06:12AM  
Nov-10-20 08:45AM  
07:28AM  
07:00AM  
Nov-03-20 12:30PM  
07:00AM  
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Sep-28-20 07:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 07:21AM  
Sep-09-20 07:00AM  
Sep-02-20 07:00AM  
Aug-19-20 07:00AM  
Aug-13-20 10:35AM  
07:30AM  
07:00AM  
Aug-06-20 12:30PM  
Aug-03-20 07:00AM  
Jul-17-20 10:29AM  
Jul-06-20 07:00AM  
Jul-05-20 04:33PM  
Jun-08-20 07:00AM  
May-26-20 04:01PM  
May-18-20 06:34AM  
May-15-20 08:52AM  
08:15AM  
07:00AM  
May-08-20 12:30PM  
May-07-20 07:00AM  
Apr-28-20 04:45PM  
Apr-27-20 12:31PM  
Apr-15-20 07:00AM  
Apr-07-20 07:00AM  
Apr-02-20 02:54PM  
Mar-12-20 07:26AM  
Mar-11-20 07:24AM  
07:00AM  
Mar-10-20 07:05AM  
Feb-21-20 07:00AM  
Jan-13-20 07:00AM  
Jan-06-20 07:00AM  
Dec-31-19 03:15PM  
07:25AM  
Dec-30-19 03:40PM  
Dec-19-19 06:28PM  
Dec-09-19 04:19PM  
08:42AM  
07:00AM  
Nov-27-19 09:24AM  
Nov-13-19 07:00AM  
Nov-12-19 07:15AM  
Nov-06-19 09:01AM  
Oct-31-19 12:20PM  
Oct-30-19 10:34AM  
06:30AM  
Oct-03-19 10:11AM  
Sep-30-19 07:58AM  
06:30AM  
Sep-26-19 06:30AM  
Sep-23-19 06:30AM  
Sep-17-19 07:10AM  
Sep-16-19 06:30AM  
Sep-04-19 06:30AM  
Aug-28-19 06:30AM  
Aug-14-19 04:30PM  
11:37AM  
Jul-22-19 08:23AM  
Jul-18-19 01:04PM  
06:30AM  
Jul-10-19 03:00PM  
Jul-05-19 01:12PM  
Jun-23-19 08:53PM  
Jun-12-19 06:30AM  
Jun-11-19 06:00AM  
May-29-19 06:30AM  
May-22-19 01:31PM  
May-14-19 06:30AM  
May-09-19 06:30AM  
Apr-29-19 07:05PM  
04:15PM  
Apr-24-19 06:30AM  
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JANTZ DEREKChief Scientific OfficerFeb 22Option Exercise0.0421,5148613,955,353Feb 24 05:46 PM
JANTZ DEREKChief Scientific OfficerFeb 22Sale12.049,660116,3063,945,693Feb 24 05:46 PM
JANTZ DEREKChief Scientific OfficerFeb 19Option Exercise0.0421,5148613,943,502Feb 22 07:03 PM
JANTZ DEREKChief Scientific OfficerFeb 19Sale11.559,663111,6083,933,839Feb 22 07:03 PM
KANE MATTHEW R.President and CEOFeb 18Option Exercise0.0421,5148611,899,151Feb 22 04:45 PM
JANTZ DEREKChief Scientific OfficerFeb 18Option Exercise0.0421,5148613,928,859Feb 22 07:03 PM
JANTZ DEREKChief Scientific OfficerFeb 18Sale12.206,87183,8263,921,988Feb 22 07:03 PM
KANE MATTHEW R.President and CEOFeb 18Sale12.239,705118,6921,889,446Feb 22 04:45 PM
KANE MATTHEW R.President and CEOFeb 17Option Exercise0.0421,5148611,887,342Feb 18 04:44 PM
KANE MATTHEW R.President and CEOFeb 17Sale12.289,705119,1771,877,637Feb 18 04:44 PM
KANE MATTHEW R.President and CEOFeb 16Option Exercise0.0421,5148611,875,525Feb 18 04:44 PM
KANE MATTHEW R.President and CEOFeb 16Sale13.309,697128,9701,865,828Feb 18 04:44 PM
JANTZ DEREKChief Scientific OfficerJan 29Option Exercise0.0421,5158613,913,789Feb 02 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 29Sale12.256,44478,9393,907,345Feb 02 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 28Option Exercise0.0421,5148613,898,718Jan 29 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 28Sale11.976,44477,1353,892,274Jan 29 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 27Option Exercise0.0421,5148613,884,252Jan 29 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 27Sale11.687,04882,3213,877,204Jan 29 05:00 PM
KANE MATTHEW R.President and CEOJan 26Option Exercise0.0421,5158611,863,708Jan 28 04:00 PM
KANE MATTHEW R.President and CEOJan 26Sale13.379,697129,6491,854,011Jan 28 04:00 PM
KANE MATTHEW R.President and CEOJan 25Option Exercise0.0421,5148611,851,888Jan 26 04:56 PM
KANE MATTHEW R.President and CEOJan 25Sale13.749,695133,2091,842,193Jan 26 04:56 PM
KANE MATTHEW R.President and CEOJan 22Option Exercise0.0421,5148611,840,592Jan 26 04:56 PM
KANE MATTHEW R.President and CEOJan 22Sale13.5310,218138,2501,830,374Jan 26 04:56 PM
THOMSON DAVID S.Chief Operating OfficerJan 21Sale16.4910,000164,900109,243Jan 25 08:00 AM
ANSARI ABIDChief Financial OfficerJun 15Option Exercise1.208,78310,540144,401Jun 17 04:00 PM
ANSARI ABIDChief Financial OfficerMay 15Option Exercise1.209,66111,576135,618May 19 07:17 AM
JANTZ DEREKChief Scientific OfficerApr 14Option Exercise1.184,3925,1833,862,738Apr 15 05:26 PM